Skip to Main Content

A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer

Conditions

Prostate

Phase I

What is the purpose of this trial?

This study will evaluate the safety and efficacy of ARV-766 in men with metastatic castration-resistant prostate cancer.

  • Trial with
    Arvinas Estrogen Receptor, Inc.
  • Start Date
    05/23/2022
  • End Date
    01/01/2100

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/24/2022
  • Study HIC
    #2000030751